In recent years, cancer immunotherapeutic approaches have emerged as promising strategies for cancer treatment, with PD-1 and CTLA-4 antibodies successfully used as checkpoint inhibitors to treat several types of cancer [8]. The gene discussed is CTLA4; the disease is cancer.